MOTS-c: The Peptide That Makes Your Cells Think You’re Exercising
A humorous, skeptical solo explainer on MOTS-c, a mitochondria-made peptide, covering its biology, the thin human evidence, community dosing reports and regulatory status.
With Dr. Alex Tatem (board-certified urologist, fellowship-trained men's health specialist)
Key moments
Tap a moment to play the video from there.
- 0:00Intro and why MOTS-c mattersTatem introduces MOTS-c as a peptide encoded in mitochondrial DNA and previews the FDA advisory committee date and the rise of social media cycles.
- 2:11Mitochondrial DNA and discoveryHe explains that MOTS-c comes from mitochondrial rather than nuclear DNA and describes its 2015 discovery by Lee and Cohen at USC.
- 4:09Why mitochondria are differentTatem covers ATP production, the bacterial origin theory and maternal inheritance, and says MOTS-c showed mitochondrial DNA also codes for signaling peptides.
- 6:46Mechanism: NRF2, AMPK, folate cycleHe describes MOTS-c signaling to the nucleus through NRF2 and activating AMPK via the folate cycle, with opposite tissue effects through CK2.
- 8:51Exercise mimetic and preclinical resultsHe calls MOTS-c an exercise mimetic and lists preclinical results in obesity, diabetes, bone loss and brain injury models.
- 9:38Human correlational dataTatem says MOTS-c levels fall with age and metabolic disease, and discusses the K14Q variant and its link to diabetes risk unless people exercise.
- 11:01The failed CB4211 trialHe summarizes the phase 1 analog trial in 23 patients, where liver enzymes improved but liver fat did not, and says the sponsor then dissolved.
- 12:08Community dosing and side effectsHe reports circulating protocols and side effects from biohacker forums, states this is not his recommendation, and notes there is no long-term safety data.
- 14:07FDA hearing and WADA banTatem describes the July 2026 compounding advisory committee review for obesity and osteoporosis, and says WADA lists MOTS-c as prohibited.
- 16:13Honest review and conclusionHe calls the biology exciting but says human interventional evidence is one disappointing trial, with no safety data past 28 days.
What the video says
Dr. Alex Tatem, who describes himself as a board-certified urologist and men's health specialist, walks through MOTS-c, a 16 amino acid peptide. He says the body makes it naturally, and that it is encoded in mitochondrial DNA inherited from the mother rather than in nuclear DNA. The video is a single-host explainer with a lot of jokes and pop-culture asides, and it states that its aim is to run a biohacking trend through the published literature.
The first half covers origins and mechanism. Tatem says MOTS-c was discovered in 2015 by Changhan Lee and Pinchas Cohen at USC and published in Cell Metabolism. He gives a short primer on mitochondria and the bacterial origin theory, then describes two main actions. In his account, MOTS-c acts as a signal from the mitochondria to the cell nucleus under stress, switching on genes tied to antioxidant defense, fat burning and building more mitochondria through NRF2. It also activates AMPK, an energy switch, by way of the folate cycle. He calls the result an exercise mimetic.
On evidence, Tatem separates three tiers. He says preclinical studies show broad effects on obesity, diabetes, bone loss and brain injury models. He describes human correlational data, including lower MOTS-c levels with age and metabolic disease and a variant called K14Q. For human intervention, he cites one phase 1 trial of a stabilized analog, CB4211, in 23 obese patients with fatty liver disease. He says liver enzymes fell versus placebo, liver fat did not differ, injection site bumps were persistent, and the company dissolved in 2023.
The last third covers use and regulation. Tatem stresses he is reporting what the biohacking community does, not recommending it, and relays circulating protocols of 5 to 15 mg injected subcutaneously three times a week for 8 to 12 weeks, followed by 4 to 8 weeks off. He lists reported benefits and side effects, notes there is no long-term human safety data, and says an FDA advisory committee hearing on July 23rd and 24th, 2026 would be a milestone rather than a finish line. He adds that WADA bans MOTS-c in elite sport. His closing view is that the biology is exciting but proof is lacking.
On each compound
MOTS-c0:34
Tatem describes MOTS-c as a 16 amino acid mitochondria-derived peptide that signals to the nucleus and activates AMPK. He cites strong preclinical and correlational support but only one failed human trial of an analog, and says long-term human safety data does not exist.
See how your DNA reads MOTS-c“promise and proof still live in different neighborhoods”
What this video doesn’t settle
- The video does not show that MOTS-c improves any clinical outcome in healthy adults, since Tatem says no randomized studies exist.
- The only human interventional data discussed is a small phase 1 trial of an analog, not MOTS-c itself.
- The dosing protocols come from biohacker forums and are not tied to any published trial.
Questions this video answers
What is MOTS-c and where does it come from?
Tatem says MOTS-c is a 16 amino acid peptide made by the body and encoded in mitochondrial DNA, which he says is inherited entirely from the mother. He says it was discovered in 2015 by Changhan Lee and Pinchas Cohen at USC.
How does MOTS-c work according to Dr. Alex Tatem?
He says it acts as a signal from mitochondria to the nucleus under stress, turning on genes via NRF2 for antioxidant defense, fat burning and mitochondrial biogenesis. He also says it activates AMPK through the folate cycle, which is why he calls it an exercise mimetic.
Has MOTS-c been tested in human clinical trials?
Tatem cites one phase 1 trial of a stabilized analog, CB4211, in 23 obese patients with fatty liver disease. He says liver enzymes dropped versus placebo but liver fat did not, and he notes no successful phase 2 or phase 3 trial exists.
What MOTS-c doses and side effects does the video describe?
Tatem reports community protocols of 5 to 15 mg subcutaneously three times a week for 8 to 12 weeks, then 4 to 8 weeks off, and says he is not recommending them. Reported side effects he lists include injection site bumps, heart palpitations, insomnia, early fatigue and hypoglycemic-like symptoms.
Is MOTS-c banned or regulated?
Tatem says the FDA's compounding advisory committee was set to review MOTS-c for obesity and osteoporosis on July 23rd and 24th, 2026, and that licensed compounding would take months even after a favorable outcome. He also says WADA lists it as prohibited in elite sport.
Video by Dr. Alex Tatem on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
